The granting of a new patent notice of allowance to Adial Pharmaceuticals by the US Patent and Trademark Office is a significant positive development. It not only enhances the company's intellectual property portfolio but also potentially secures a competitive edge in its market segment. This development could lead to increased investor confidence and a positive impact on the company's stock price in the short term.